MindWalk Holdings (HYFT) Exchange Rate Effect (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Exchange Rate Effect of -$14590.1 for Q2 2026, up 96.52% year-over-year from -$7424.2 in Q2 2025, and up 94.73% quarter-over-quarter from -$276698.8 in Q1 2026.
MindWalk Holdings (HYFT) Exchange Rate Effect (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Exchange Rate Effect for 4 consecutive years, with -$14590.1 the latest figure, recorded in Q2 2026.
- In Q2 2026, Exchange Rate Effect rose 96.52% year-over-year to -$14590.1; the TTM figure through Apr 2026 stood at -$370191.9 (down 17.37% YoY), while the FY2026 annual figure was -$374966.1, down 19.25% from the prior year.
- Exchange Rate Effect improved to -$14590.1 in Q2 2026 per HYFT's latest filing, from -$276698.8 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $432737.1 in Q1 2024 and bottomed at -$894612.1 in Q2 2024.
- Historically, Exchange Rate Effect has averaged -$89264.3 across 4 years, with a median of -$76337.6 in 2023.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect sank 7665.57% — and 2025, when it surged 136.65%.
- MindWalk Holdings' Exchange Rate Effect stood at -$50887.1 in 2023, then slumped by 100.03% to -$101788.1 in 2024, then slipped by 18.27% to -$120386.8 in 2025, then surged by 87.88% to -$14590.1 in 2026.
- Business Quant data shows HYFT's Exchange Rate Effect at -$14590.1 in Q2 2026, -$276698.8 in Q1 2026, and -$120386.8 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -14,590.12 |
| Apr 30, 2026 | -14,590.12 |
| Jan 31, 2026 | -276,698.76 |
| Jan 31, 2026 | -276,698.76 |
| Oct 31, 2025 | -120,386.79 |
| Oct 31, 2025 | -120,386.79 |
| Jul 31, 2025 | 41,483.76 |
| Jul 31, 2025 | 41,483.76 |
| Apr 30, 2025 | -419,529.03 |
| Apr 30, 2025 | -419,529.03 |
| Jan 31, 2025 | 319,105.36 |
| Jan 31, 2025 | 319,105.36 |
| Oct 31, 2024 | -101,788.13 |
| Oct 31, 2024 | -101,788.13 |
| Jul 31, 2024 | -113,198.36 |
| Jul 31, 2024 | -113,198.36 |
| Apr 30, 2024 | -894,612.10 |
| Apr 30, 2024 | -894,612.10 |
| Jan 31, 2024 | 432,737.06 |
| Jan 31, 2024 | 432,737.06 |